Gonadotrophin‐releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome?
Open Access
- 1 May 2008
- journal article
- Published by Wiley in BJU International
- Vol. 101 (11) , 1335-1336
- https://doi.org/10.1111/j.1464-410x.2008.07707.x
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Metabolic changes during gonadotropin‐releasing hormone agonist therapy for prostate cancerCancer, 2008
- Adipocytokines, Obesity, and Insulin Resistance During Combined Androgen Blockade for Prostate CancerUrology, 2008
- Diagnosis and Classification of Diabetes MellitusDiabetes Care, 2008
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- Metabolic Syndrome in Men With Prostate Cancer Undergoing Long-Term Androgen-Deprivation TherapyJournal of Clinical Oncology, 2006
- Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemiaClinical Science, 2003
- Changes in Bone Mineral Density, Lean Body Mass and Fat Content as Measured by Dual Energy X-Ray Absorptiometry in Patients With Prostate Cancer Without Apparent Bone Metastases Given Androgen Deprivation TherapyJournal of Urology, 2002
- Changes in Body Composition during Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Endocrinology & Metabolism, 2002
- The Effects of Induced Hypogonadism on Arterial Stiffness, Body Composition, and Metabolic Parameters in Males with Prostate CancerJournal of Clinical Endocrinology & Metabolism, 2001
- Effects of the Luteinizing Hormone-Releasing Hormone Agonist Leuprolide on Lipoproteins, Fibrinogen and Plasminogen Activator Inhibitor in Patients with Benign Prostatic HyperplasiaJournal of Urology, 1995